Risk of Recurrent Venous Thromboembolism and Bleeding in Cancer Patients Treated With Direct Oral Anticoagulants Versus Low-molecular-weight Heparin.
Risk of Recurrent Venous Thromboembolism and Bleeding in Cancer Patients Treated With Direct Oral Anticoagulants Versus Low-molecular-weight Heparin. Acad Emerg Med. 2020 Feb; 27(2):170-172.